Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report

Abstract

Esophageal spindle cell carcinoma (ESpCC) is a rare subtype of esophageal carcinoma, accounting for 1% of all esophageal malignancies. The clinical outcome is unknown due to the lack of treatment options. Here, we present the case of a 60‐year‐old male with initially unresectable ESpCC, in which platinum‐based concurrent chemoradiotherapy was unsuccessful. He was subsequently treated with neoadjuvant immunotherapy and after surgery achieved a complete pathological response; therefore, neoadjuvant immunotherapy might be a novel option for ESpCC patients.

Multiregion exome sequencing indicates a monoclonal origin of esophageal spindle‐cell squamous cell carcinoma

“…Several reported cases of ESS demonstrated the potential effectiveness of additional therapeutic options on top of standard surgical resection, including endoscopic therapy [42,43], (neoadjuvant) chemotherapy, or radiotherapy alone [12,13,44]. Fu et al [14] described the case of a 60-year-old man with unresectable ESS who received immunotherapy after concomitant chemoradiotherapy failed; the patient achieved a complete pathological response after surgery. In our study, patient P23 developed lung metastases after four cycles of chemotherapy and then received a combination therapy based on camrelizumab for 1 year; this is the only surviving stage III patient in our cohort at present.…”

“…At present, radical resection with lymph node dissection remains the primary treatment for ESS [9][10][11]; however, there has been controversy regarding the potential survival benefits of radiation and chemotherapy [12][13][14][15]. Owing to the low number of cases reported and heterogeneity among patients, the prognosis of ESS remains unclear, particularly when compared to that of esophageal squamous cell carcinoma (ESCC).…”

Primary maxillary sinus carcinosarcoma with multidisciplinary management: a case report with 4 years follow-up and literature review

“…The diagnosis was demonstrated by postoperative SS18 gene testing, histopathology, and immunohistochemistry. According to the available data, the treatment of SpCC might be different from that of CS [ 33 ]. Indeed, a case of inoperable esophageal SpCC showed no response to platinum-based chemoradiotherapy, but neoadjuvant immunotherapy was successful, and the tumor could be removed.…”